Prediction of new polymorph of the Alzheimer's drug, piracetam

NewsGuard 100/100 Score

A challenge, presented at last year's e-Science All Hands meeting, has resulted in an e-Science project achieving one of the holy grails of the pharmaceutical industry - the computational prediction of a previously unidentified crystal structure, or polymorph, of a drug molecule.

Researchers working on the e-materials project picked up the gauntlet and successfully predicted a new polymorph of the Alzheimer's drug, piracetam. The work of the e-materials project will be presented at this year's e-Science All Hands meeting which is being held in Nottingham from 20-22 September 2005.

The action of a drug is dependent not only on its chemical composition, but also on the way in which the drug molecules arrange themselves. For example, crystal structure can affect the drug's solubility and hence its rate of absorption into the bloodstream. An unexpected polymorph could alter the drug's therapeutic properties if it inadvertently contaminated the standard formulation.

Polymorphs are the bane of the pharmaceutical industry because they can be difficult to predict. Industrial chemists put a lot of effort into searching for new polymorphs using experimental techniques, but they can never be sure they have found them all. A new polymorph can turn up years later, sometimes resulting in the withdrawal of a drug from the market whilst the problem is identified and solved. Pharmaceutical companies are also keen to patent every polymorph of a drug to prevent a rival from undercutting them later with a new, therapeutically effective version.

The e-materials project, funded by the Engineering and Physical Sciences Research Council (EPSRC) as part of the e-Science Core Programme, is applying Grid technologies to address this problem. "We chose to study piracetam because it's a well understood drug with three known polymorphs. We thought it was a good one to test our new methods against," says Professor Sally Price from University College, London (UCL).

After presenting her work at last year's e-Science All Hands meeting, Professor Price was presented with a challenge. Dr Colin Pulham from the University of Edinburgh asked her to predict the crystal structure of a new polymorph of piracetam that he had discovered using high pressure crystallisation techniques. "I told Professor Price that we had discovered a new form, but I didn't tell her what is was. If her techniques were effective, she should be able to find it," he says.

Predicting polymorphism in molecular structures is computationally very demanding. Millions of possible structures need to be analysed to identify those that are likely to be the most stable. Professor Price conducted the piracetam analysis on a campus grid at UCL. The e-materials project is building up a database containing the outputs of polymorphism searches and analysis at the Central Laboratory for the Research Councils (CCLRC). The database and a dataportal will shortly be available on the National Grid Service, providing information on an increasing range of molecules that may help identify other new polymorphs.

A few months after her challenge, Professor Price submitted a list of candidate structures in order of probability. The first on the list matched the structure that Dr Pulham and his team had found experimentally. "It was bang, spot on," he says. "This result does a lot for the credibility of our methodology," adds Professor Price.

The two continue to collaborate over other molecular polymorphisms, with Professor Price's predictions of new polymorphs guiding Dr Pulham's experiments, as well as vice versa. The next challenge is to develop the new e-Science techniques further to find polymorphism in increasingly complex molecules.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer